Please login to the form below

Not currently logged in
Email:
Password:

Sanofi wins EU approval for new diabetes combination Suliqua

European Commission licenses the once-daily version of Lantus and Lyxumia
Sanofi

Sanofi's combination therapy Suliqua has been granted European marketing approval for the treatment of adults with type 2 diabetes.

The dual-drug treatment combines the firm's blockbuster Lantus (insulin glargine) and with Lyxumia (lixisenatide) and aims to improve glycaemic control for those where metformin alone or in combination is not sufficient.

Approval of the once-daily injection was based on two phase III studies - LixiLan-O and LixiLan-L - which showed Suliqua to be statistically superior in reducing blood sugar levels in comparison with both Lyxumia and Lantus.

Dr Elias Zerhouni, president of global R&D at Sanofi, said: “Suliqua is an innovative new combination therapy that has the potential to address significant unmet needs for people living with type 2 diabetes in Europe.

“The approval of Suliqua represents the successful culmination of a concerted effort by Sanofi scientists to bring two injectable treatments together in a single and precisely titratable dose.

“Sanofi has a long history of elevating care for people with diabetes, and we believe Suliqua will make it easier for patients with inadequately controlled diabetes to reach their treatment goals.”

The long-acting basal insulin and GLP-1 agonist is already on the market in the US as Soliqua, having been approved by the FDA in November last year on the same day as rival therapy Xultophy, Novo Nordisk's insulin degludec and liraglutide combination.

In the EU, however, Xultophy has the edge as it received regulatory approval in 2014 in Europe, where it is marketed as IDegLira.

Both companies are vying for market share in the sector, but analysts have predicted Xultophy will take the lead with sales of $1.2bn by 2021 in comparison with the $550m forecast for Suliqua.

Article by
Rebecca Clifford

18th January 2017

From: Regulatory

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Iguazu

Iguazu Ltd is a digital healthcare agency, delivering tactical and innovative solutions. WHAT WE DO We are Closed Loop Marketing...

Latest intelligence

The Patient Will See You Now – The Evolution of the Doctor-Patient Relationship
The doctor-patient relationship is an ever changing one that changes as society changes. Technology then helps to drive this change along with a wide number of other factors....
Mind the Gap – Challenging Immunisation Apathy and Misinformation
world, the biggest challenges remain apathy and misinformation. Since a measles vaccine was introduced in the UK in 1968, Public Health England estimates that 20 million measles cases and 4,500...
Towards Better HCP Engagement – An Email Masterclass
6% of HCPs prefer being contacted by email, compared to 17% who favour the second most popular option: direct interaction with reps....